XXXX in @entity303 : a controlled study.

@entity1 @entity303 @entity9398 @entity1502 @entity195
The effect of @entity1502 on mental state of @entity1 suffering from @entity195 ( @entity195 ) and @entity9398 ( @entity9398 ) was investigated in a double-blind study. After an initial 2-weeks washout period, the @entity1 were randomly selected to receive either 400 mg @entity1502 thrice daily or matched placebo tablets for 12 weeks. Eighteen male and 18 female @entity1 aged 60-88 years were included but 5 @entity1 dropped out during the first 2 weeks of the trial due to poor motivation. Two @entity1 for non compliance and one for protocol violation were further excluded from final analysis. The age and sex distribution of the @entity1 receiving placebo were comparable to those of treated @entity1 . The mean pre-entry severity of @entity303 , as assessed by Folstein's mini mental state (FMMS) and Sandoz Clinical Assessment Geriatric Scale (SCAGS), was greater in the latter group (p less than 0.05). Although both groups showed slight improvement at the end of 12 weeks' treatment, no significant drug-related progress was observed. However, the @entity9398 @entity1 (n = 4) who received @entity1502 showed greater improvement (p less than 0.05) than the @entity9398 @entity1 (n = 7) who were treated with placebo. No such benefit was observed in @entity1502 -treated @entity195 @entity1 . It is, therefore, suggested, that @entity1502 (a haemorrheological agent), is probably beneficial only in @entity9398 @entity1 , but further long-term studies involving a larger number of @entity1 are required.
